RxDoctor Payments Data

Felipe Villa Martignoni, MD

Internal Medicine · Lubbock, TXNPI 1104277946

Payments from drug & device makers

$4,581in general payments, 2019–2025

Across 53 payments — averaging $86.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Medtronic$702
  • Abiomed$550
  • Abbott$238
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$167
  • Edwards Lifesciences$162
  • plus $330 from 5 others

What the payments were for

  • Travel & lodging$1,50133%
  • Food & beverage$2,82862%
  • Education$2525%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,581 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$12,798
Medicare patients
78
Services billed
202

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban142$127,524
OzempicSemaglutide106$119,459
XareltoRivaroxaban31$28,758
FarxigaDapagliflozin Propanediol40$27,279
RybelsusSemaglutide19$19,264
JardianceEmpagliflozin13$16,918
JanuviaSitagliptin Phosphate11$12,650
Fluticasone-SalmeterolFluticasone Propion/Salmeterol41$11,986
Incruse ElliptaUmeclidinium Bromide16$5,721
Breo ElliptaFluticasone/Vilanterol11$4,940
SymbicortBudesonide/Formoterol Fumarate12$2,773
Metoprolol Succinate180$2,556
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid21$2,396
Atorvastatin Calcium284$2,173
Memantine Hcl13$2,173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$135$30,05252 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →